ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer
November 16 2021 - 6:30AM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Kristen Harrington-Smith has been appointed
Senior Vice President and Chief Commercial Officer.
"We are excited that Kristen has joined ImmunoGen's management
team at such an important time, as we look forward to reporting
top-line data from our pivotal SORAYA trial this quarter and
prepare for the potential launch of mirvetuximab soravtansine next
year," said Mark Enyedy, ImmunoGen's President and Chief Executive
Officer. "With over two decades of commercial experience in the
pharmaceutical industry, Kristen brings invaluable knowledge to
ImmunoGen that will serve us well as we look to build a
best-in-class commercial organization and continue to advance our
pipeline of innovative ADCs targeting solid tumors and hematologic
malignancies."
Ms. Harrington-Smith joins ImmunoGen from Novartis
Pharmaceuticals, where she served as US Commercial Head of
Hematology and led the teams responsible for a broad portfolio of
therapies in both benign and malignant hematologic diseases. Prior
to this, Ms. Harrington-Smith held roles of increasing
responsibility at Novartis, including leading the commercial launch
of Kymriah®, the first CAR-T cell therapy, building management,
sales, and marketing teams, and supporting the launch of Gilenya®
for the treatment of multiple sclerosis. Ms. Harrington-Smith
received a BA from Williams College and an MBA from the
Kenan-Flagler Business School at the University of North
Carolina.
"I am thrilled to join ImmunoGen at this pivotal moment in the
company's evolution and look forward to contributing to a
successful transition to a commercial oncology company," said Ms.
Harrington-Smith. "I believe ImmunoGen's portfolio of
next-generation ADCs has the potential to change the course of
cancer care, and I am excited to help bring these novel therapies
to patients in need."
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug
conjugates (ADCs) to improve outcomes for cancer patients. By
generating targeted therapies with enhanced anti-tumor activity and
favorable tolerability profiles, we aim to disrupt the progression
of cancer and offer our patients more good days. We call this our
commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on
management's current expectations. These statements include, but
are not limited to, ImmunoGen's expectations related to: the
occurrence, timing, and outcome of potential preclinical, clinical,
and regulatory events related to the Company's product candidates,
in particular with respect to the potential launch of mirvetuximab
soravtansine; the presentation of preclinical and clinical data on
the Company's product candidates, including with respect to
mirvetuximab soravtansine; and the Company's business and product
development strategies. For these statements, ImmunoGen claims the
protection of the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
Various factors could cause ImmunoGen's actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. Factors that could cause future results to
differ materially from such expectations include, but are not
limited to: the timing and outcome of the Company's preclinical and
clinical development processes; the difficulties inherent in the
development of novel pharmaceuticals, including uncertainties as to
the timing, expense, and results of preclinical studies, clinical
trials, and regulatory processes; the Company's ability to
financially support its product programs; risks and uncertainties
associated with the scale and duration of the COVID-19 pandemic and
the resulting impact on ImmunoGen's industry and business; and
other factors as set forth in the Company's Annual Report on Form
10-K filed with the Securities and Exchange Commission on March 1,
2021, and other reports filed with the Securities and Exchange
Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211116005083/en/
INVESTOR RELATIONS AND MEDIA CONTACTS ImmunoGen Courtney
O'Konek 781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Sep 2023 to Sep 2024